Japan
# |
Name |
EBITDA Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
55.70%
|
Dec. 31, 2023 | USD 21.58 | 0.31% |
|
Japan |
|
2 |
50.06%
|
March 31, 2024 | USD 14.75 | -0.46% |
|
Japan |
|
3 |
48.66%
|
Dec. 31, 2023 | USD 9.76 | -1.43% |
|
Japan |
|
4 |
42.80%
|
Dec. 31, 2023 | USD 43.39 | 5.16% |
|
Japan |
|
5 |
37.52%
|
Aug. 31, 2024 | USD 9.32 | -2.24% |
|
Japan |
|
6 |
36.20%
|
March 31, 2024 | USD 10.39 | -0.80% |
|
Japan |
|
7 |
34.33%
|
Dec. 31, 2023 | USD 5.86 | -2.20% |
|
Japan |
|
8 |
34.24%
|
Sept. 30, 2024 | USD 2.93 | -1.24% |
|
Japan |
|
9 |
33.95%
|
March 31, 2024 | USD 10.95 | -0.53% |
|
Japan |
|
10 |
32.70%
|
March 31, 2024 | USD 9.15 | -1.97% |
|
Japan |
|
11 |
32.20%
|
Dec. 31, 2023 | USD 13.83 | -0.63% |
|
Japan |
|
12 |
29.51%
|
June 30, 2024 | USD 16.87 | -2.21% |
|
Japan |
|
13 |
29.16%
|
Dec. 31, 2023 | USD 3.39 | -1.15% |
|
Japan |
|
14 |
28.96%
|
Oct. 31, 2023 | USD 5.47 | -1.74% |
|
Japan |
|
15 |
28.50%
|
March 31, 2024 | USD 25.58 | -1.99% |
|
Japan |
|
16 |
27.38%
|
March 31, 2024 | USD 31.28 | -0.59% |
|
Japan |
|
17 |
26.80%
|
Dec. 31, 2023 | USD 14.95 | -1.71% |
|
Japan |
|
18 |
26.34%
|
Sept. 30, 2024 | USD 9.46 | -2.05% |
|
Japan |
|
19 |
26.30%
|
March 31, 2024 | USD 4.97 | -1.23% |
|
Japan |
|
20 |
26.19%
|
March 31, 2024 | USD 43.36 | -1.17% |
|
Japan |
|
21 |
26.10%
|
March 31, 2024 | USD 24.26 | -0.77% |
|
Japan |
|
22 |
26.02%
|
Aug. 31, 2024 | USD 13.43 | 0.52% |
|
Japan |
|
23 |
26.02%
|
Dec. 31, 2023 | USD 3.77 | -0.24% |
|
Japan |
|
24 |
25.85%
|
Dec. 31, 2023 | USD 9.78 | -1.94% |
|
Japan |
|
25 |
25.06%
|
March 31, 2024 | USD 19.21 | -1.38% |
|
Japan |
|
26 |
24.77%
|
March 31, 2024 | USD 25.51 | -0.96% |
|
Japan |
|
27 |
24.58%
|
March 31, 2024 | USD 10.75 | -2.71% |
|
Japan |
|
28 |
24.56%
|
March 31, 2024 | USD 3.56 | -3.55% |
|
Japan |
|
29 |
24.11%
|
March 31, 2024 | USD 9.19 | -0.31% |
|
Japan |
|
30 |
23.83%
|
March 31, 2024 | USD 18.88 | -4.20% |
|
Japan |
|
31 |
23.69%
|
Sept. 30, 2024 | USD 12.23 | -2.54% |
|
Japan |
|
32 |
23.14%
|
March 31, 2024 | USD 14.41 | -0.72% |
|
Japan |
|
33 |
20.85%
|
March 31, 2024 | USD 12.96 | -0.41% |
|
Japan |
|
34 |
20.63%
|
Oct. 31, 2024 | USD 76.41 | -0.92% |
|
Japan |
|
35 |
20.51%
|
March 31, 2024 | USD 27.12 | 0.10% |
|
Japan |
|
36 |
20.40%
|
March 31, 2024 | USD 29.51 | -0.48% |
|
Japan |
|
37 |
20.18%
|
March 31, 2024 | USD 3.38 | -1.89% |
|
Japan |
|
38 |
20.15%
|
Sept. 30, 2024 | USD 3.00 | -0.80% |
|
Japan |
|
39 |
19.07%
|
March 31, 2024 | USD 27.56 | -3.63% |
|
Japan |
|
40 |
18.98%
|
March 31, 2024 | USD 11.36 | -0.42% |
|
Japan |
|
41 |
18.83%
|
March 31, 2024 | USD 29.12 | 0.44% |
|
Japan |
|
42 |
18.70%
|
March 31, 2024 | USD 8.69 | -1.39% |
|
Japan |
|
43 |
18.49%
|
March 31, 2024 | USD 17.95 | -0.66% |
|
Japan |
|
44 |
18.45%
|
March 31, 2024 | USD 13.76 | -1.19% |
|
Japan |
|
45 |
18.16%
|
March 31, 2024 | USD 6.66 | -1.06% |
|
Japan |
|
46 |
18.14%
|
Dec. 31, 2023 | USD 8.94 | -0.23% |
|
Japan |
|
47 |
17.45%
|
March 31, 2024 | USD 27.19 | -2.00% |
|
Japan |
|
48 |
17.20%
|
Feb. 29, 2024 | USD 28.70 | -1.67% |
|
Japan |
|
49 |
16.89%
|
May 31, 2024 | USD 13.38 | -1.63% |
|
Japan |
|
50 |
16.36%
|
March 31, 2024 | USD 12.31 | 0.15% |
|
Japan |
The Healthcare company in Japan with the highest EBITDA Margin is GNI Group Ltd. (Tokyo Stock Exchange: 2160.T) at 55.70%.
The Healthcare company in Japan with the lowest EBITDA Margin is BrightPath Biotherapeutics Co., Ltd. (Tokyo Stock Exchange: 4594.T) at -1,619,147.22%.
The top 10 Healthcare companies in Japan by EBITDA Margin are GNI Group Ltd., Shionogi & Co., Ltd., Mizuho Medy Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Mani, Inc., Ono Pharmaceutical Co., Ltd., FINDEX Inc., Kanamic Network Co.,LTD, Shin Nippon Biomedical Laboratories, Ltd. and M3, Inc..
The bottom 10 Healthcare companies in Japan by EBITDA Margin are BrightPath Biotherapeutics Co., Ltd., Oncolys BioPharma Inc., NanoCarrier Co., Ltd., OncoTherapy Science, Inc., MEDINET Co., Ltd., Solasia Pharma K.K., Welby Inc., Carna Biosciences, Inc., Nxera Pharma Co., Ltd. and Precision System Science Co., Ltd..